Last reviewed · How we verify
Cyclovegantine (DROFENINE)
Cyclovegantine (generic name: DROFENINE) is a drug. It is currently in Phase 2 development.
Cyclovexgantine works by binding to specific proteins or receptors in the body to produce a therapeutic effect.
Cyclovexgantine, also known as DROFENINE, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. The approved indications for Cyclovexgantine are also unknown. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. Further research is needed to fully understand its mechanism of action and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DROFENINE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and Cyclovexgantine is a key that fits into those locks. When it binds to the right lock, it can help to turn off or turn on certain cellular processes that are involved in the disease it's being used to treat. This can help to restore balance to the body's normal functioning.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclovegantine CI brief — competitive landscape report
- Cyclovegantine updates RSS · CI watch RSS
Frequently asked questions about Cyclovegantine
What is Cyclovegantine?
How does Cyclovegantine work?
What is the generic name of Cyclovegantine?
What development phase is Cyclovegantine in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing